Serum Leucine-Rich α2 Glycoprotein: A Novel Biomarker for Transmural Inflammation in Crohn's Disease

INTRODUCTION: Leucine-rich alpha-2 glycoprotein (LRG) is a newly studied biomarker for inflammatory diseases. This study aimed to investigate whether LRG can be used for evaluating transmural activity in patients with Crohn's disease (CD). METHODS: We performed magnetic resonance enterography (MRE) in 227 consecutive patients with CD from June 2020 to August 2021. We prospectively compared MRE findings with clinical and laboratory data including LRG. MRE was evaluated using 2 validated scoring systems, and transmural inflammation was defined as having a maximum simplified magnetic resonance index of activity (sMaRIA) score of >= 4 and a 5-point classification score of >= 9, respectively. RESULTS: The correlation between LRG and the total MRE score showed a positive correlation (r = 0.576 for the sMaRIA score, P < 0.01, and r = 0.633 for the 5-point score, P < 0.01). Serum concentrations of LRG significantly increased as MRE scores increased (P < 0.01). The area under the curve of LRG for a sMaRIA score of >= 4 and a 5-point score of >= 9 was 0.845 and 0.869, respectively, which was significantly higher than that of CDAI (P < 0.01) or C-reactive protein (P < 0.01). LRG levels of >= 14 mg/mL had a 67% sensitivity and 90% specificity for a sMaRIA score of v4 and a 73% sensitivity and 89% specificity for a 5-point score of >= 9. Patients with high LRG levels were also strongly associated with CD-related hospitalization, surgery, and clinical relapse compared with those with low LRG levels (P < 0.01 for all). DISCUSSION: LRG is a highly accurate serum biomarker for detecting transmural activity in patients with CD. Results need to be validated in further multicenter studies.

Automated summary

This study investigates the use of LRG as a biomarker for evaluating transmural activity in patients with Crohn's disease (CD). The results show a positive correlation between LRG levels and MRE scores, indicating that LRG is a highly accurate biomarker for detecting transmural activity in CD patients. Furthermore, high LRG levels are associated with increased risks of CD-related hospitalization, surgery, and clinical relapse.